CCM
KRYS icon

Consonance Capital Management’s Krystal Biotech KRYS Stock Holding History

Consonance Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-654,586
Closed -$28.3M – 35
2020
Q1 		$28.3M Buy
654,586
+450,798
+221% +$23.6M 2.11% 20
2019
Q4 		$11.3M Sell
203,788
-20,302
-9% -$996K 0.69% 30
2019
Q3 		$7.78M Buy
224,090
+42,000
+23% +$1.88M 0.77% 25
2019
Q2 		$7.33M Buy
+182,090
New +$5.95M 0.52% 26

Other funds holding KRYS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Consonance Capital Management's KRYS Position: Q2 2020 in Review

Consonance Capital Management sold out of Krystal Biotech (KRYS) in Q2 2020, closing a stake of 654,586 shares — an estimated $28.3M sold.

Consonance Capital Management first reported a position in KRYS in Q2 2019 and held it in 4 quarters. The position peaked at $28.3M in Q1 2020. 110 funds tracked by Wall St. Rank hold KRYS as of Q2 2020.

  • Consonance Capital Management reported no remaining Krystal Biotech position as of Q2 2020 after selling out during the quarter.
  • Consonance Capital Management sold 654,586 Krystal Biotech shares in Q2 2020, an estimated $28.3M.
  • Consonance Capital Management first reported a position in Krystal Biotech in Q2 2019 and held it in 4 quarters.
  • Consonance Capital Management's Krystal Biotech position peaked at $28.3M in Q1 2020.
  • 110 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2020.

Based on Consonance Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.